Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Cell. 2006 Nov;10(5):343-5.

Restoring cancer's death sentence.

Author information

1
Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Dana 530B, Boston, Massachusetts 02115, USA. anthony_letai@dfci.harvard.edu

Abstract

In this issue of Cancer Cell, two groups present data on the function of an antagonist of BCL-2, ABT-737. Both groups find that expression of MCL-1, an antiapoptotic protein related to BCL-2, is a key determinant of resistance to ABT-737. Lowering MCL-1 levels is an effective adjunct to BCL-2 antagonism, and both groups suggest ways that this might be accomplished practically in a clinical setting. The mechanism by which ABT-737 selectively kills cancer cells is discussed below in the context of these and prior reports of ABT-737's function. Antagonism of BCL-2 is an exciting anticancer strategy that may soon become a clinical reality.

PMID:
17097553
DOI:
10.1016/j.ccr.2006.10.014
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center